{
    "nct_id": "NCT02405221",
    "official_title": "A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients With History of HPV16 Associated Cervical Cancer",
    "inclusion_criteria": "1. Patients with HPV16 related stage IB1-IV cervical cancer who completed definitive treatment within 12 months\n2. Patients with no evidence of disease recurrence within 8 weeks of enrollment\n3. Documented to have HPV16 nucleic acid within the cervical tumor specimen as determined by in situ hybridization\n4. Fresh-frozen or paraffin-embedded material must be available for in situ hybridization testing for HPV16 nucleic acid for central confirmation\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1\n6. Adequate organ function as defined by study-specified laboratory tests\n7. Ability to understand and willingness to sign a written informed consent document\n8. Willing and able to comply with study schedule and other protocol requirements\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "1. Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions\n2. Patients with a diagnosis of immunosuppression or prolonged, active use of immunosuppressive agents such as systemic steroids\n3. Prior HPV vaccination\n4. Had surgery, chemotherapy, or radiation therapy within 28 days prior to receiving study drug\n5. Another investigational product within 28 days prior to receiving study drug\n6. Active or chronic HIV, HBV, or HCV infection\n7. Pregnant or lactating\n8. Patients who have an active autoimmune disease\n9. Patients with a recognized immunodeficiency disease or are being chronically treated with immunosuppressive drugs\n10. Women of childbearing potential\n11. Patients with non-healed wounds\n12. A history of current or recent concurrent malignancy (â‰¤5 years) except basal cell cancer.\n13. Inability to understand or unwillingness to sign an informed consent document",
    "miscellaneous_criteria": ""
}